2](https://file.medchemexpress.com/product_pic/hy-158117.gif "Click to View [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
943 Results for "
adventitial fibroblast
" in MedChemExpress (MCE) Product Catalog:
Products (943)
943 Results for "adventitial fibroblast" in MCE Product Catalog:
Cat. No.: HY-P85626A
Synonyms: 18A2; 42A; calcium Placental protein; Calvasculin; CAPL; fibroblast specific protein 1; fibroblast specific protein; FSP1; Leukemia multidrug resistance associated protein; Malignant transformation suppression 1; Metastasin; MTS1; OTTHUMP00000015467; OTTHUMP00000015468; P9KA; PEL98; Placental calcium-binding protein; Protein Mts1; Protein S100 A4; Protein S100-A4; S100 calcium binding protein A4; calcium protein, calvasculin, metastasin, murine placental homolog; S100 calcium binding protein A4; S100 calcium-binding protein A4; S100a4; S10A4_HUMAN.
Cat. No.: HY-P76338
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FGFR2; Protein Tyrosine Kinase, Receptor Like 14; Prev. KGFR; fibroblast Growth Factor Receptor; Prev. BEK; Receptor Protein-Tyrosine Kinase; Prev. CFD1; Craniofacial Dysostosis 1; Prev. JWS; Alternative Protein FGFR2; Keratinocyte Growth Factor Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-P78125
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: FGFR2; Protein Tyrosine Kinase, Receptor Like 14; Prev. KGFR; fibroblast Growth Factor Receptor; Prev. BEK; Receptor Protein-Tyrosine Kinase; Prev. CFD1; Craniofacial Dysostosis 1; Prev. JWS; Alternative Protein FGFR2; Keratinocyte Growth Factor Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-P78129
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: FGFR2; Protein Tyrosine Kinase, Receptor Like 14; Prev. KGFR; fibroblast Growth Factor Receptor; Prev. BEK; Receptor Protein-Tyrosine Kinase; Prev. CFD1; Craniofacial Dysostosis 1; Prev. JWS; Alternative Protein FGFR2; Keratinocyte Growth Factor Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-P78130
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: FGFR2; Protein Tyrosine Kinase, Receptor Like 14; Prev. KGFR; fibroblast Growth Factor Receptor; Prev. BEK; Receptor Protein-Tyrosine Kinase; Prev. CFD1; Craniofacial Dysostosis 1; Prev. JWS; Alternative Protein FGFR2; Keratinocyte Growth Factor Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-P78131
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: FGFR2; Protein Tyrosine Kinase, Receptor Like 14; Prev. KGFR; fibroblast Growth Factor Receptor; Prev. BEK; Receptor Protein-Tyrosine Kinase; Prev. CFD1; Craniofacial Dysostosis 1; Prev. JWS; Alternative Protein FGFR2; Keratinocyte Growth Factor Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-P705827
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FGFR2; Protein Tyrosine Kinase, Receptor Like 14; Prev. KGFR; fibroblast Growth Factor Receptor; Prev. BEK; Receptor Protein-Tyrosine Kinase; Prev. CFD1; Craniofacial Dysostosis 1; Prev. JWS; Alternative Protein FGFR2; Keratinocyte Growth Factor Receptor
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-128795
CAS No.: 2095304-61-1
Research Areas:
KH176m is the major active metabolite of KH176 (HY-121577). KH176m is a microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor that can cross the blood-brain barrier, with an IC50 of 0.16 µM against mouse mPGES-1 and 1.51 µM against human mPGES-1. KH176m blocks LPS- or IL-1β-induced PGE2 production, scavenges ROS, inhibits lipid peroxidation, accelerates NADPH consumption, suppresses the growth of prostate cancer spheroids, reduces the CD44 + CD24 − prostate cancer stem cell population, and protects fibroblasts with oxidative phosphorylation defects from redox stress-induced death. KH176m can be used in research related to mitochondrial diseases, inflammatory pain, inflammatory neurological diseases, inflammatory cancers, and prostate cancer .
Cat. No.: HY-139062
CAS No.: 486991-52-0
Synonyms: C6 Ceramide (d18:1/6:0) Urea; Cer(d18:1/6:0) Urea; D-erythro-Urea-C6-Ceramide
Target:
Research Areas:
C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.
Cat. No.: HY-158117
[Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 (Compound 3) is a copper complex, which inhibits cell viability of HCT116, HCT116DoxR, A2780 and fibroblasts, with IC50s of 0.13, 0.15, 0.66 and 6.24 μM, respectively. [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 induces apoptosis and autophagy, and arrests cell cycle at G0/G1 phase in HCT116DoxR. [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 exhibits antimetastatic efficacy .
Cat. No.: HY-180556
Research Areas:
PI3K/mTOR-IN-20 is a selective dual PI3K/mTOR inhibitor. PI3K/mTOR-IN-20 demonstrates nanomolar antiproliferative effects with IC50s of 0.380 and 0.090 μM for MRC-5 and Mlg2908 cells. PI3K/mTOR-IN-20 reduces Ashcroft scores, hydroxyproline content, collagen deposition, and downregulates fibrosis-related proteins, while restoring lung architecture in a Bleomycin-induced pulmonary fibrosis model. PI3K/mTOR-IN-20 shows a favorable safety profile with steady weight recovery and no distinct liver or kidney toxicity. PI3K/mTOR-IN-20 can be used for fetal lung fibroblasts research .
Cat. No.: HY-L088
3,660 compounds
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).
MCE offers a unique collection of 3,660 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.
Cat. No.: HY-P7186
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CXCL1; Neutrophil-Activating Protein 3; Prev. GRO1; fibroblast Secretory Protein; Prev. MGSA; C-X-C Motif Chemokine 1; Prev. FSP; GRO-Alpha(1-73); SCYB1; GRO1 Oncogene (Melanoma Growth-Stimulating Activity); NAP-3; Melanoma Growth Stimulatory Activity Alp
Species:
Mouse
Source:
CHO
Cat. No.: HY-P7187
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CXCL1; Neutrophil-Activating Protein 3; Prev. GRO1; fibroblast Secretory Protein; Prev. MGSA; C-X-C Motif Chemokine 1; Prev. FSP; GRO-Alpha(1-73); SCYB1; GRO1 Oncogene (Melanoma Growth-Stimulating Activity); NAP-3; Melanoma Growth Stimulatory Activity Alp
Species:
Human
Source:
E. coli
Cat. No.: HY-P7189
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CXCL1; Neutrophil-Activating Protein 3; Prev. GRO1; fibroblast Secretory Protein; Prev. MGSA; C-X-C Motif Chemokine 1; Prev. FSP; GRO-Alpha(1-73); SCYB1; GRO1 Oncogene (Melanoma Growth-Stimulating Activity); NAP-3; Melanoma Growth Stimulatory Activity Alp
Species:
Rat
Source:
E. coli
Cat. No.: HY-P7363
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CXCL1; Neutrophil-Activating Protein 3; Prev. GRO1; fibroblast Secretory Protein; Prev. MGSA; C-X-C Motif Chemokine 1; Prev. FSP; GRO-Alpha(1-73); SCYB1; GRO1 Oncogene (Melanoma Growth-Stimulating Activity); NAP-3; Melanoma Growth Stimulatory Activity Alp
Species:
Human
Source:
CHO
Cat. No.: HY-P72649
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FGF4; Heparin-Binding Growth Factor 4; Prev. HSTF1; HSTF-1; HBGF-4; FGF-4; HST-1; Heparin Secretory-Transforming Protein 1; HST; fibroblast Growth Factor; Transforming Protein KS3; Oncogene HST; K-FGF; SRTD22; KFGF; KS3; Human Stomach Cancer, Transforming
Species:
Mouse
Source:
E. coli
Cat. No.: HY-P76335
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FGFR2; Protein Tyrosine Kinase, Receptor Like 14; Prev. KGFR; fibroblast Growth Factor Receptor; Prev. BEK; Receptor Protein-Tyrosine Kinase; Prev. CFD1; Craniofacial Dysostosis 1; Prev. JWS; Alternative Protein FGFR2; Keratinocyte Growth Factor Receptor
Species:
Human
Source:
HEK293
Cat. No.: HY-P700558
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CXCL1; Neutrophil-Activating Protein 3; Prev. GRO1; fibroblast Secretory Protein; Prev. MGSA; C-X-C Motif Chemokine 1; Prev. FSP; GRO-Alpha(1-73); SCYB1; GRO1 Oncogene (Melanoma Growth-Stimulating Activity); NAP-3; Melanoma Growth Stimulatory Activity Alp
Species:
Human
Source:
E. coli
Cat. No.: HY-P700559
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CXCL1; Neutrophil-Activating Protein 3; Prev. GRO1; fibroblast Secretory Protein; Prev. MGSA; C-X-C Motif Chemokine 1; Prev. FSP; GRO-Alpha(1-73); SCYB1; GRO1 Oncogene (Melanoma Growth-Stimulating Activity); NAP-3; Melanoma Growth Stimulatory Activity Alp
Species:
Mouse
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
